Double Bond Pharmaceutical International AB (DBP B) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Double Bond Pharmaceutical International AB

Why is Double Bond Pharmaceutical International AB ?

Unrated Stock - No Analysis Available

Real-Time Research Report

Verdict Report

No Data Found

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-13.30%

EBIT Growth (5y)

9.55%

EBIT to Interest (avg)

-14.66

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.87

Sales to Capital Employed (avg)

0.22

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

EV to EBIT

0.07

EV to EBITDA

0.07

EV to Capital Employed

-0.19

EV to Sales

-0.39

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-302.41%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bullish

Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

10What is working for the Company

RAW MATERIAL COST(Y)

Fallen by -99.79% (YoY

DEBT-EQUITY RATIO (HY)

Lowest at -87.11 %

OPERATING PROFIT(Q)

Highest at SEK -0.35 MM

PRE-TAX PROFIT(Q)

At SEK -1.1 MM has Grown at 55.66%

NET PROFIT(Q)

At SEK -1.1 MM has Grown at 55.66%

-11What is not working for the Company

NET SALES(HY)

At SEK 0.22 MM has Grown at -68.66%

ROCE(HY)

Lowest at -252.07%

Here's what is working for Double Bond Pharmaceutical International AB

Operating Profit

Highest at SEK -0.35 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (SEK MM)

Pre-Tax Profit

At SEK -1.1 MM has Grown at 55.66%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (SEK MM)

Net Profit

At SEK -1.1 MM has Grown at 55.66%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is positive

Net Profit (SEK MM)

Debt-Equity Ratio

Lowest at -87.11 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost

Fallen by -99.79% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Double Bond Pharmaceutical International AB

Net Sales

At SEK 0.22 MM has Grown at -68.66%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very negative

Net Sales (SEK MM)